JP5198266B2 - 放射性表面源及びその作成方法 - Google Patents
放射性表面源及びその作成方法 Download PDFInfo
- Publication number
- JP5198266B2 JP5198266B2 JP2008523530A JP2008523530A JP5198266B2 JP 5198266 B2 JP5198266 B2 JP 5198266B2 JP 2008523530 A JP2008523530 A JP 2008523530A JP 2008523530 A JP2008523530 A JP 2008523530A JP 5198266 B2 JP5198266 B2 JP 5198266B2
- Authority
- JP
- Japan
- Prior art keywords
- radionuclide
- atoms
- radioactive
- polymeric material
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims description 96
- 239000000463 material Substances 0.000 claims description 74
- 238000001959 radiotherapy Methods 0.000 claims description 32
- 229910052751 metal Inorganic materials 0.000 claims description 30
- 239000002184 metal Substances 0.000 claims description 30
- 230000004907 flux Effects 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 22
- 239000002861 polymer material Substances 0.000 claims description 21
- 239000011253 protective coating Substances 0.000 claims description 20
- 230000005855 radiation Effects 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 18
- 230000005258 radioactive decay Effects 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 229960005562 radium-223 Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims description 9
- HCWPIIXVSYCSAN-YPZZEJLDSA-N radium-224 Chemical compound [224Ra] HCWPIIXVSYCSAN-YPZZEJLDSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 7
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 7
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 claims description 7
- 239000012811 non-conductive material Substances 0.000 claims description 6
- 238000009987 spinning Methods 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- 229910052705 radium Inorganic materials 0.000 claims description 5
- 229920001169 thermoplastic Polymers 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000001746 injection moulding Methods 0.000 claims description 3
- 239000004416 thermosoftening plastic Substances 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 33
- 239000002245 particle Substances 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 18
- 238000003795 desorption Methods 0.000 description 12
- 230000005262 alpha decay Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000005255 beta decay Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 6
- 229910052719 titanium Inorganic materials 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 206010027406 Mesothelioma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 238000002725 brachytherapy Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001552 radio frequency sputter deposition Methods 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- HZEBHPIOVYHPMT-OUBTZVSYSA-N Polonium-210 Chemical compound [210Po] HZEBHPIOVYHPMT-OUBTZVSYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- SYUHGPGVQRZVTB-OIOBTWANSA-N radon-219 atom Chemical compound [219Rn] SYUHGPGVQRZVTB-OIOBTWANSA-N 0.000 description 2
- SYUHGPGVQRZVTB-YPZZEJLDSA-N radon-220 atom Chemical compound [220Rn] SYUHGPGVQRZVTB-YPZZEJLDSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 239000012815 thermoplastic material Substances 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000033014 Plasma cell tumor Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 1
- 229920005648 ethylene methacrylic acid copolymer Polymers 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 201000009593 extraosseous chondrosarcoma Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000001891 gel spinning Methods 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229940049705 immune stimulating antibody conjugate Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- WABPQHHGFIMREM-BJUDXGSMSA-N lead-206 Chemical compound [206Pb] WABPQHHGFIMREM-BJUDXGSMSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 208000029986 neuroepithelioma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000034655 secondary growth Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 230000005428 wave function Effects 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
本発明を本書では、単なる例示として、添付の図面を参照して説明する。今、特に図面を詳細に参照すると、図示する細部は例であって、本発明の好適な実施形態の例証説明を目的としているにすぎず、発明の原理および概念的側面の最も有用かつ分かり易い記述であると信じられるものを提供するために提示することを強調しておく。これに関し、発明の詳細を発明の基本的理解に必要である以上に詳しく示そうとはせず、図面に照らした記述は、本発明の幾つかの形態をいかに実際に具現することができるかを、当業者に明らかにする。
図1〜2は、本発明の様々な例示的実施態様による、放射線治療のための放射性表面源の作成方法のフローチャート図である。
図3a−bは、本発明の様々な例示的実施態様における放射性表面源の概略図である。
図4は、本発明の様々な例示的実施態様の教示による、生体吸収性糸から作られた放射性表面源の概略図である。
Ra−223はアルファ崩壊によって11.4dの半減期でRn−219に崩壊する:
Rn−219はアルファ崩壊によって4sの半減期でPo−215に崩壊する;
Po−215はアルファ崩壊によって1.8msの半減期でPb−211に崩壊する;
Pb−211はベータ崩壊によって36mの半減期でBi−211に崩壊する;
Bi−211はアルファ崩壊によって2.1mの半減期でTl−207に崩壊する;
Tl−207はベータ崩壊によって4.8mの半減期で安定したPb−207に崩壊する。
Ra−224はアルファ崩壊によって3.7dの半減期でRn−220に崩壊する;
Rn−220はアルファ崩壊によって56sの半減期でPo−216に崩壊する;
Po−216はアルファ崩壊によって0.15sの半減期でPb−212に崩壊する;
Pb−212はベータ崩壊によって10.6hの半減期でBi−212に崩壊する;
Bi−212はアルファ崩壊によって1hの半減期でTl−208(36%分岐比)に、又はベータ崩壊によってPo−212(64%分岐比)に崩壊する。
Tl−208はベータ崩壊によって3mの半減期で安定したPb−208に崩壊する;
Po−212はアルファ崩壊によって0.3μsの半減期で安定したPb−208に崩壊する。
本発明の様々な例示的実施態様に従って試作品の生体吸収性放射性表面源40を作った。試作品の表面源は図4に概略的に示されている。3〜0ゲージ(約0.3ミリメートルの直径d)の生体吸収性縫合糸42を表面源の構造体として使用した。糸はモノフィラメントグリコマー(glycomer)(No.631;BIOSYN(登録商標)のGM−332)から作られた。
Claims (35)
- 放射線治療のための放射性表面源を作成するための方法であって、以下の工程を含む方法:
(a)表面を有する構造体を準備する;
(b)前記表面の上又は真下に少なくとも一種の放射性核種の原子を収集するように前記少なくとも一種の放射性核種の流束中に前記構造体を位置させる;そして
(c)前記原子が前記表面中に挿入されるが放射性崩壊時に前記表面から外に反跳することができるように前記表面に熱処理を適用する、ただし、前記熱処理は、加熱後の冷却を含む。 - 前記熱処理の適用は、前記表面の下の前記原子の拡散を起こすために十分な選択された予め決められた温度に前記表面を加熱することを含む、請求項1に記載の方法。
- 前記工程(b)の前に、前記原子が前記少なくとも一つの層中に収集されるように、ポリマー材料の少なくとも一つの層によって前記表面を被覆することをさらに含む、請求項1に記載の方法。
- 前記ポリマー材料の少なくとも一つの層を流体で処理し、前記少なくとも一つの層から前記少なくとも一種の放射性核種の残留原子を除去することをさらに含む、請求項3に記載の方法。
- 前記熱処理の適用は、前記ポリマー材料を溶融するのに十分な選択された予め決められた温度に前記表面を加熱し、それによって前記原子を前記ポリマー材料中に挿入することを含む、請求項3に記載の方法。
- 前記表面を被覆することは、浸漬、紡糸、インフレーション及び射出成形からなる群から選択される方法によって実施される、請求項3に記載の方法。
- 前記構造体は非導電性材料から作られ、前記工程(a)は、少なくとも一つの金属層によって前記構造体を少なくとも部分的に被覆し、それによって前記表面を形成することをさらに含む、請求項1に記載の方法。
- 放射線治療のための放射性表面源を作成するための方法であって、以下の工程を含む方法:
(a)非導電性材料から作られた構造体を準備する;
(b)前記構造体を少なくとも一つの金属層によって少なくとも部分的に被覆し、それによって表面を形成する;そして
(c)前記表面の上又は真下に少なくとも一種の放射性核種の原子を収集するように前記少なくとも一つの放射性核種の流束中に前記構造体を位置させる。 - 前記非導電性材料は生体吸収性材料を含む、請求項8に記載の方法。
- 保護被覆によって前記表面を少なくとも部分的に被覆することをさらに含む、請求項8に記載の方法。
- 前記表面から前記少なくとも一種の放射性核種の残留原子を除去するように前記表面を流体で処理することをさらに含む、請求項1又は8に記載の方法。
- 前記保護被覆から前記少なくとも一種の放射性核種の残留原子を除去するように前記保護被覆を流体で処理することをさらに含む、請求項10に記載の方法。
- 前記残留原子の量が予め決められたしきい値以下になるまで少なくとも一回、前記流体での処理を繰り返すことをさらに含む、請求項11又は12に記載の方法。
- 前記少なくとも一種の放射性核種の原子は、真空下での直接埋め込みによって収集される、請求項1又は8に記載の方法。
- 前記少なくとも一種の放射性核種の原子は、前記表面を負の極性の電圧源に接続することによって収集される、請求項1又は8に記載の方法。
- 前記少なくとも一種の放射性核種の流束中に前記構造体を位置させることは、ガス環境下で実施される、請求項15に記載の方法。
- 前記ガス環境の圧力及び前記電圧源の電圧は、前記原子の速度が熱速度に低下されるように選択される、請求項16に記載の方法。
- 放射線治療のための放射性表面源であって、ポリマー材料の少なくとも一つの層によって被覆される構造体、及び前記ポリマー材料中に挿入されるが放射性崩壊時に前記ポリマー材料から外へ反跳することができる少なくとも一種の放射性核種の原子を含む、放射性表面源。
- 前記ポリマー材料の表面が流体に接触するとき、前記表面からの前記原子の除去が実質的に防止される、請求項18に記載の放射性表面源。
- 少なくとも一種の放射性核種の原子を有する少なくとも一つの金属層によって少なくとも部分的に被覆された生体吸収性材料から作られた構造体を含む、放射線治療のための放射性表面源であって、前記原子は前記少なくとも一つの金属層中に挿入されるが放射性崩壊時に前記少なくとも一つの金属層から外へ反跳することができる、放射性表面源。
- 前記少なくとも一つの金属層を少なくとも部分的に被覆する保護被覆をさらに含む、請求項20に記載の放射性表面源。
- ポリマー材料、及び少なくとも一種の放射性核種の原子を含む組成物であって、前記原子は前記ポリマー材料中に挿入されるが放射性崩壊時に前記ポリマー材料から外に反跳することができる、組成物。
- 前記少なくとも一種の放射性核種の原子は、前記表面の数オングストローム下にある、請求項2又は8に記載の方法。
- 前記少なくとも一種の放射性核種はラジウムを含む、請求項1又は8に記載の方法。
- 前記ラジウムはラジウム−223及びラジウム−224からなる群から選択される、請求項24に記載の方法。
- 前記ポリマー材料は熱可塑性ポリマー材料を含む、請求項3に記載の方法。
- 前記ポリマー材料はポリメチルメタクリレートを含む、請求項3に記載の方法。
- 放射性表面源は、治療される組織において約10〜約100グレイに等価な放射線量によって特徴づけられる、請求項1又は8に記載の方法。
- 前記少なくとも一種の放射性核種の放射能は約10ナノキュリー〜約10マイクロキュリーである、請求項1又は8に記載の方法。
- 前記原子は、1秒あたり約102〜約105個の核の出て行く流束で放射性表面源から外へ崩壊系列核を放射することができる、請求項1又は8に記載の方法。
- 前記少なくとも一種の放射性核種の表面密度は約1010〜約1013原子/cm2である、請求項1又は8に記載の方法。
- 前記構造体は金属から作られる、請求項1に記載の方法。
- 前記構造体は、針状物、ワイヤ、ビーズ、内視鏡の先端、腹腔鏡の先端、及び撮像装置の先端からなる群から選択される、請求項1に記載の方法。
- 前記構造体は、縫合糸である、請求項8に記載の方法。
- 前記構造体は、縫合糸である、請求項20に記載の放射性表面源。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70228805P | 2005-07-26 | 2005-07-26 | |
US60/702,288 | 2005-07-26 | ||
PCT/IL2006/000850 WO2007013060A2 (en) | 2005-07-26 | 2006-07-23 | A radioactive surface source and a method for producing the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009503491A JP2009503491A (ja) | 2009-01-29 |
JP2009503491A5 JP2009503491A5 (ja) | 2009-08-13 |
JP5198266B2 true JP5198266B2 (ja) | 2013-05-15 |
Family
ID=37649290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008523530A Active JP5198266B2 (ja) | 2005-07-26 | 2006-07-23 | 放射性表面源及びその作成方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090136422A1 (ja) |
EP (2) | EP1909855B8 (ja) |
JP (1) | JP5198266B2 (ja) |
KR (1) | KR20080030073A (ja) |
CN (1) | CN101272810B (ja) |
AU (1) | AU2006273680A1 (ja) |
CA (1) | CA2615589A1 (ja) |
CY (2) | CY1120604T1 (ja) |
DK (2) | DK1909855T3 (ja) |
ES (2) | ES2701409T3 (ja) |
HU (2) | HUE041388T2 (ja) |
LT (2) | LT2510952T (ja) |
PL (2) | PL2510952T3 (ja) |
PT (2) | PT2510952T (ja) |
SI (2) | SI1909855T1 (ja) |
WO (1) | WO2007013060A2 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1644049B1 (en) | 2003-04-30 | 2007-09-26 | Ramot at Tel Aviv University Ltd. | Method and device for radiotherapy |
US9821174B1 (en) | 2015-02-06 | 2017-11-21 | Gammatile Llc | Radioactive implant planning system and placement guide system |
US10888710B1 (en) | 2016-11-29 | 2021-01-12 | Gt Medical Technologies, Inc. | Transparent loading apparatus |
CN108267773B (zh) * | 2017-01-03 | 2022-05-20 | 中国辐射防护研究院 | 一种微沉淀法制备钋的α测量源的方法 |
RU2763750C2 (ru) * | 2017-05-11 | 2022-01-10 | Альфа Тау Медикал Лтд. | Полимерные покрытия для брахитерапевтических устройств |
CN111052262A (zh) * | 2017-06-29 | 2020-04-21 | 南非核能Soc有限公司 | 放射性同位素的制备 |
AU2019229849B2 (en) | 2018-03-08 | 2021-07-15 | Alpha Tau Medical Ltd. | Radiotherapy seeds and applicators |
KR20200139722A (ko) * | 2018-04-02 | 2020-12-14 | 알파 타우 메디컬 리미티드 | 방사성 핵종의 제어된 방출 |
JP2022505022A (ja) | 2018-11-01 | 2022-01-14 | アルファ タウ メディカル リミテッド | 腫瘍内アルファ放射体放射と細胞内病原体に対する細胞質プラズマセンサーの活性化 |
CN109994243B (zh) * | 2019-04-03 | 2024-07-30 | 原子高科股份有限公司 | 一种放射源及其制备方法 |
AU2021379123B2 (en) | 2020-11-12 | 2024-06-13 | Alpha Tau Medical Ltd. | Radiotherapy template assembly |
JP2024503995A (ja) | 2020-12-16 | 2024-01-30 | アルファ タウ メディカル リミテッド | ベータ線治療を強化した拡散アルファ放射体放射線治療 |
KR20230156328A (ko) | 2021-03-11 | 2023-11-14 | 알파 타우 메디컬 리미티드 | 방사선치료 어플리케이터 |
US12070621B2 (en) | 2021-06-10 | 2024-08-27 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for pancreatic cancer |
US12076582B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for colorectal cancer |
US12064643B2 (en) | 2021-06-10 | 2024-08-20 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for breast cancer |
US12042668B2 (en) | 2021-06-10 | 2024-07-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for squamous cell carcinoma |
US11964168B2 (en) | 2021-06-10 | 2024-04-23 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for prostate cancer |
US12070620B2 (en) | 2021-06-10 | 2024-08-27 | Alpha Tau Medical Ltd. | Activity levels for diffusing alpha-emitter radiation therapy |
US12076581B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for glioblastoma |
US12076583B2 (en) | 2021-06-10 | 2024-09-03 | Alpha Tau Medical Ltd. | Diffusing alpha-emitter radiation therapy for melanoma |
CN113436775B (zh) * | 2021-06-23 | 2022-11-08 | 中国核动力研究设计院 | 一种无衬底超薄镍-63放射源的制备方法 |
WO2023275770A1 (en) | 2021-06-30 | 2023-01-05 | Alpha Tau Medical Ltd. | Radiotherapy applicator with perpendicular or angled radial dispensing |
US12053644B2 (en) | 2021-12-30 | 2024-08-06 | Gt Medical Technologies, Inc. | Radiation shielding apparatus for implantable radioactive seeds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107283A (en) * | 1976-07-19 | 1978-08-15 | New England Nuclear Corporation | Tracer for circulation determinations |
US5342283A (en) * | 1990-08-13 | 1994-08-30 | Good Roger R | Endocurietherapy |
JP3636851B2 (ja) * | 1996-11-29 | 2005-04-06 | 株式会社ニデック | 灌流吸引装置 |
US5906573A (en) * | 1997-07-18 | 1999-05-25 | Radiomed Corporation | Radioactive surgical fastening devices and methods of making same |
US6030333A (en) * | 1997-10-24 | 2000-02-29 | Radiomed Corporation | Implantable radiotherapy device |
US6394945B1 (en) * | 1997-12-22 | 2002-05-28 | Mds (Canada), Inc. | Radioactively coated devices |
US6296831B1 (en) * | 1998-04-10 | 2001-10-02 | Battelle Memorial Institute | Stimulus sensitive gel with radioisotope and methods of making |
US6248057B1 (en) * | 1998-07-28 | 2001-06-19 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
US6575888B2 (en) * | 2000-01-25 | 2003-06-10 | Biosurface Engineering Technologies, Inc. | Bioabsorbable brachytherapy device |
CA2320557A1 (en) * | 2000-09-25 | 2002-03-25 | Michelangelo Delfino | Radioactive medical implant and method of manufacturing |
EP1232770A1 (en) * | 2001-02-15 | 2002-08-21 | AEA Technology QSA GmbH | Radioactive capsule seed |
EP1644049B1 (en) * | 2003-04-30 | 2007-09-26 | Ramot at Tel Aviv University Ltd. | Method and device for radiotherapy |
-
2006
- 2006-07-23 SI SI200632262T patent/SI1909855T1/en unknown
- 2006-07-23 DK DK06766165.2T patent/DK1909855T3/en active
- 2006-07-23 LT LTEP12165220.0T patent/LT2510952T/lt unknown
- 2006-07-23 SI SI200632304T patent/SI2510952T1/sl unknown
- 2006-07-23 PT PT12165220T patent/PT2510952T/pt unknown
- 2006-07-23 EP EP06766165.2A patent/EP1909855B8/en active Active
- 2006-07-23 DK DK12165220.0T patent/DK2510952T3/en active
- 2006-07-23 ES ES12165220T patent/ES2701409T3/es active Active
- 2006-07-23 PL PL12165220T patent/PL2510952T3/pl unknown
- 2006-07-23 KR KR1020087002633A patent/KR20080030073A/ko not_active Application Discontinuation
- 2006-07-23 AU AU2006273680A patent/AU2006273680A1/en not_active Abandoned
- 2006-07-23 HU HUE12165220A patent/HUE041388T2/hu unknown
- 2006-07-23 LT LTEP06766165.2T patent/LT1909855T/lt unknown
- 2006-07-23 US US11/989,202 patent/US20090136422A1/en not_active Abandoned
- 2006-07-23 CA CA002615589A patent/CA2615589A1/en not_active Abandoned
- 2006-07-23 ES ES06766165.2T patent/ES2671719T3/es active Active
- 2006-07-23 JP JP2008523530A patent/JP5198266B2/ja active Active
- 2006-07-23 CN CN2006800351764A patent/CN101272810B/zh active Active
- 2006-07-23 EP EP12165220.0A patent/EP2510952B8/en active Active
- 2006-07-23 WO PCT/IL2006/000850 patent/WO2007013060A2/en active Application Filing
- 2006-07-23 PL PL06766165T patent/PL1909855T3/pl unknown
- 2006-07-23 HU HUE06766165A patent/HUE037796T2/hu unknown
- 2006-07-23 PT PT67661652T patent/PT1909855T/pt unknown
-
2018
- 2018-05-25 CY CY181100564T patent/CY1120604T1/el unknown
- 2018-12-10 CY CY181101311T patent/CY1120981T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK1909855T3 (en) | 2018-06-14 |
ES2671719T3 (es) | 2018-06-08 |
ES2701409T8 (es) | 2019-05-27 |
EP2510952A1 (en) | 2012-10-17 |
US20090136422A1 (en) | 2009-05-28 |
JP2009503491A (ja) | 2009-01-29 |
LT1909855T (lt) | 2018-05-25 |
WO2007013060A2 (en) | 2007-02-01 |
AU2006273680A1 (en) | 2007-02-01 |
EP1909855A2 (en) | 2008-04-16 |
PT2510952T (pt) | 2018-12-18 |
CN101272810B (zh) | 2013-12-04 |
ES2701409T3 (es) | 2019-02-22 |
HUE037796T2 (hu) | 2018-09-28 |
WO2007013060A3 (en) | 2007-05-24 |
CY1120604T1 (el) | 2019-12-11 |
PL1909855T3 (pl) | 2018-09-28 |
SI1909855T1 (en) | 2018-06-29 |
EP1909855B1 (en) | 2018-03-07 |
KR20080030073A (ko) | 2008-04-03 |
PL2510952T3 (pl) | 2019-05-31 |
DK2510952T3 (en) | 2019-01-07 |
CA2615589A1 (en) | 2007-02-01 |
SI2510952T1 (sl) | 2019-01-31 |
CY1120981T1 (el) | 2019-12-11 |
HUE041388T2 (hu) | 2021-12-28 |
PT1909855T (pt) | 2018-06-11 |
LT2510952T (lt) | 2018-12-10 |
EP2510952B8 (en) | 2019-03-20 |
EP2510952B1 (en) | 2018-09-12 |
ES2671719T8 (es) | 2019-05-27 |
EP1909855B8 (en) | 2019-03-20 |
CN101272810A (zh) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5198266B2 (ja) | 放射性表面源及びその作成方法 | |
AU2010201870B2 (en) | Method and Device for Radiotherapy | |
KR20200139722A (ko) | 방사성 핵종의 제어된 방출 | |
EP1815873B1 (en) | Method and device for radiotherapy | |
AU2004233763B2 (en) | Method and device for radiotherapy | |
IL207737A (en) | Method of preparing a radioactive surface source | |
IL207738A (en) | Method of manufacturing a radiotherapy device | |
IL171629A (en) | Device for radiotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090629 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111025 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130206 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160215 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5198266 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |